06821.HK
Asymchem Laboratories (Tianjin) Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 103.90
−1.14%Year over year
Reported trailing growth
- Revenue
- +17.5%
- EBITDA
- +6.8%
- EBIT
- +12.7%
- EPS
- +15.7%
- Free cash flow
- —
- Operating cash flow
- -14.5%
Forward estimates
Based on analyst estimates
- Revenue
- -65.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.4%
- EBITDA
- -23.2%
- EBIT
- -30.5%
- Net income
- -30.0%
- EPS
- -29.3%
- Free cash flow
- -50.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026